Compass Therapeutics Inc Ordinary Shares CMPX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Trading Information
- Previous Close Price
- $2.10
- Day Range
- $2.01–2.12
- 52-Week Range
- $1.61–6.88
- Bid/Ask
- $2.03 / $2.12
- Shares Outstanding
- 180.09M
- Market Cap
- $369.18M
- Volume/Avg
- 2M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 39
Valuation
|
Metric
|
CMPX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.98 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CMPX
Financial Strength
|
Metric
|
CMPX
|
|---|---|
Quick Ratio | 18.94 |
Current Ratio | 19.04 |
Interest Coverage | — |
Quick Ratio
CMPX
Profitability
|
Metric
|
CMPX
|
|---|---|
Return on Assets (Normalized) | −31.66% |
Return on Equity (Normalized) | −35.94% |
Return on Invested Capital (Normalized) | −33.99% |
Return on Assets
CMPX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g>WXB! | LOCK|$K^n | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V@q<Mq | LOCK|!Ssd | $71B | |||
| argenx SE ADR
ARGX
| LOCK|fkv&?c> | LOCK|@y | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|tZ@W@<? | LOCK|?$k | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|V>K<>C^ | LOCK|!hr$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%!H?Xkz | LOCK|KMF< | $26B | |||
| Moderna Inc
MRNA
| LOCK|$<^$YJ | LOCK|%h& | $25B | |||
| Incyte Corp
INCY
| LOCK|Cy#q<VN | LOCK|@L | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Hw>@X>R | LOCK|JX | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|tjjQcx | LOCK|d? | $16B |
United States